Effect of Dolutegravir Intensification on HIV-1 Reservoirs (EDIT)

  • days left to enroll
  • participants needed
  • sponsor
    University of Liege
Updated on 17 May 2022


Persistent HIV viremia occurs in most ART-treated patients and could arise from reactivation of viral expression from latently-infected cells that constitute the viral latent reservoir (LR) and/or residual ongoing viral replication during cART, for instance in anatomical compartment where drug penetration is sub-optimal.

The question of the sources of persistent viremia is of the utmost importance. If ongoing viral replication occurs, it could induce deleterious consequences on reservoirs size and immune activation.We propose to better characterize the role ongoing viral replication to HIV persistence under ART by undertaking a treatment intensification trial with high-dose dolutegravir. Tissue/blood samples and replication-competent reservoir measurements will be included as outcomes as well as immune activation markers.

Condition HIV-1-infection
Treatment Dolutegravir 50 mg
Clinical Study IdentifierNCT05351684
SponsorUniversity of Liege
Last Modified on17 May 2022


Yes No Not Sure

Inclusion Criteria

HIV-infected adults receiving cART for at least 3 years
Undetectable viral for at least 3 years
DTG/3TC/ABC as cART regimen in the previous 6 months
CD4 counts higher than 200 cells per μL

Exclusion Criteria

active hepatitis C or B
unstable liver disease
renal impairment (estimated glomerular filtration rate <50 mL per min)
gastrointestinal disorders that would affect the absorption of study treatment
current use of drugs with significant interactions with dolutegravir
current use of drugs with an impact on inflammation such as steroids
hospitalization for acute illness within the previous 8 weeks
Pregnancy or breastfeeding
Anal or rectal lesions impeding rectal biopsies
Decreased platelets count or coagulation disorder
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note